Alliance Announces FDA Approval of Atezolizumab Based on Results from the Phase III ATOMIC Trial for Patients with Stage III dMMR Colon Cancer

October 9, 2026

Chicago, IL - The Alliance for Clinical Trials in Oncology (Alliance) today announced that the U.S. Food and Drug Administration has approved the immunotherapy drug atezolizumab (Tecentriq^®) in combination with fluoropyrimidine and oxaliplatin chemotherapy, for the adjuvant treatment of patients with stage III colo

• Read more

Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with SignateraTM MRD-Guided CDK4/6 Inhibitor Therapy in ER-Positive/HER2-Negative Early-Stage Breast Cancer

Trial will utilize Natera’s ultrasensitive MRD test, Signatera Genome with Phased and Structural Variants, paired with giredestrant monotherapy, Genentech’s oral SERD, with the objective

• Read more

Sharing News from the Alliance: September Media Mentions

October 4, 2026 - The media relations efforts from Alliance staff and researchers are designed to alert the public about the vital work happening across our network. When we share stories about clinical trial results, scientific milestones, or investigator achievements, we are showcasing the real-world progress you help make possible.

See where the Alliance was mentioned September 2026 in the links below.

Alliance trial

• Read more